Results 11 to 20 of about 11,553 (254)

Use of the impella system in high-risk patients undergoing non-cardiac surgery: a pilot study [PDF]

BMC Anesthesiology
Background Patients with advanced heart failure are often deemed ineligible for non-cardiac surgery (NCS) due to poor hemodynamic reserve and increased perioperative risk.
Stefano Guarracini, Lorenzo Mazzocchetti, Andrea Italiano, Leonardo Paloscia, Massimo Di Marco, Fabio Francesco Di Mola, Pierluigi Di Sebastiano, Tommaso Grottola, Gabriele Tovalieri, Giovanni Di Ianni, Mirta D’Orazio, Goffredo Liberatoscioli, Michele Di Mauro   +12 more
doaj   +2 more sources

Percutaneous Temporary Mechanical Circulatory Support as a Bridge to Heart Transplantation in the Current UNOS Allocation System [PDF]

Biomedicines
Background: Progressive heart failure cardiogenic shock (HFCS) often requires escalation to temporary or durable mechanical circulatory support (MCS) as a bridge to transplant (BTT).
Rohan Goswami, Jose Ruiz, Aarti Desai, Peter Wlodkowski, Basar Sareyyupoglu, Sean Kiley, Anirban Bhattacharyya, Daniel Yip, Melissa Lyle, Jose Nativi-Nicolau, Juan Leoni, Devang Sanghavi, Alfredo Quiñones-Hinojosa, Sanjay Chaudhary, Kevin Landolfo, Si Pham, Parag Patel   +16 more
doaj   +2 more sources

Impella-Induced Incessant Ventricular Tachycardia [PDF]

Ochsner Journal, 2019
Background: The Impella 2.5 and Impella Cardiac Power (CP) devices (ABIOMED) are used to provide mechanical circulatory support for high-risk percutaneous coronary interventions or cardiogenic shock as a bridge to recovery or destination therapy.
Amir Kaki, Ahmed Subahi, Mohamed Shokr, Walid Ibrahim, Ahmed Yassin, Reema Hasan, M. Chadi Alraies, Theodore Schreiber   +7 more
openalex   +3 more sources

Weaning from Impella and mobilization of Impella patients [PDF]

European Heart Journal Supplements, 2021
AbstractWeaning of patients from Impella is complex and includes evaluation of the underlying disease, which is essential for estimating the potential for heart recovery. Monitoring during the weaning phase with echocardiography and pulmonary artery catheters will be discussed, as well as the use of intravenous and oral heart failure drugs.
Bertoldi, Letizia Fausta, Montisci, Andrea, Delmas, Clement, Pappalardo, Federico   +3 more
openaire   +2 more sources

Impella-Supported Cardiac Surgery

Interventional Cardiology, 2020
Background: Impella left ventricular assist devices are useful tools for the treatment of cardiogenic shock. The peri-operative use of Impella in patients with low left ventricular ejection fraction (LVEF) undergoing cardiac surgery, can be valuable for cardiac surgeons to prevent postcardiotomy cardiogenic shock. Methods: From September 2018
Paolo Masiello, Generoso Mastrogiovanni, Mario Colombino, Francesco Pio Cafarelli, Francesco Frunzo, Marco Padula, Donato Triggiani, Gerardo Del Negro, Emanuele Fiore, Severino Iesu   +9 more
openalex   +2 more sources

Thrombocytopenia with Impella: Not a HIT [PDF]

Catheterization and Cardiovascular Interventions, 2023
Key Points The Impella percutaneous microaxial ventricular assist device provides significant ventricular unloading, but at the cost of increased major bleeding, hemolysis, and thrombocytopenia. The present study shows that nearly all patients develop thrombocytopenia within 7 days of Impella insertion with 81% having a >50% decrease.
Arnold H. Seto, Morton J. Kern
openalex   +3 more sources

Effect of Impella 5.5 on Preexisting Functional Mitral Regurgitation in Patients with Heart Failure–Related Cardiogenic Shock

Structural Heart, 2022
Background: Heart failure–related cardiogenic shock (HF-CS) is increasingly common. Moderate/severe functional mitral regurgitation (FMR) is commonly seen in patients presenting with decompensated heart failure and is associated with worse outcomes ...
Rachna Kataria, MD, Abdurrahman Khalil, MD, Erin Coglianese, MD, Jerome Crowley, MD, Michael G. Silverman, MD, Kenneth Shelton, MD, Eriberto Michel, MD, David D’Alessandro, MD, Van-Khue Ton, MD, PhD   +8 more
doaj   +1 more source

Protective effect of the Impella on the left ventricular function after acute broad anterior wall ST elevation myocardial infarctions with cardiogenic shock: cardiovascular magnetic resonance imaging strain analysis

BMC Cardiovascular Disorders, 2022
Background The clinical efficacy of the Impella for high-risk percutaneous coronary intervention (PCI) and cardiogenic shock remains under debate. We thus sought to investigate the protective effects on the heart with the Impella’s early use pre-PCI ...
Daisuke Fukamachi, Akimasa Yamada, Akihito Ohgaku, Yutaka Koyama, Hidesato Fujito, Riku Arai, Yasunari Ebuchi, Suguru Migita, Tomoyuki Morikawa, Masaki Monden, Norio Takei, Takehiro Tamaki, Keisuke Kojima, Naotaka Akutsu, Nobuhiro Murata, Yuki Saito, Daisuke Kitano, Mitsumasa Sudo, Yasuo Okumura   +18 more
doaj   +1 more source

Outcome of Patients Supported by Large Impella Systems After Re-implantation Due to Continued or Recurrent Need of Temporary Mechanical Circulatory Support

Frontiers in Cardiovascular Medicine, 2022
Despite the growing utilization of a large microaxial pump, i. e., Impella 5.0 or 5.5 (Abiomed Inc., Danvers, MA, USA) (Impella 5+) for patients with cardiogenic shock (CS), adverse events including the necessity of re-implantation have not been well ...
Yukiharu Sugimura, Sebastian Bauer, Moritz Benjamin Immohr, Arash Mehdiani, Philipp Rellecke, Ralf Westenfeld, Hug Aubin, Udo Boeken, Artur Lichtenberg, Payam Akhyari   +9 more
doaj   +1 more source

Use of Impella Devices for Acute Cardiogenic Shock in the Perioperative Period of Cardiac Surgery

Brazilian Journal of Cardiovascular Surgery, 2022
Introduction: The Impella ventricular support system is a device that can be inserted percutaneously or directly across the aortic valve to unload the left ventricle.
Serge Sicouri, Vishal N. Shah, Meghan Buckley, Nicholas Imperato, Jacqueline McGee, Elena Casanova, Eric Gnall, Konstadinos A. Plestis   +7 more
doaj   +1 more source